Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

Final phase 2a results showed that CAN-2409 led to a median overall survival of 24.5 months in immune checkpoint ...

Verastem (NASDAQ:VSTM – Get Free Report) and Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) are both small-cap medical ...

Researchers discovered peptides that permanently block a key cancer protein once thought untreatable, using a new screening ...

Bayer, Puhe BioPharma ink global license pact to develop, manufacture and commercialize the MTA-cooperative PRMT5 inhibitor: Berlin, Germany Saturday, March 29, 2025, 12:00 Hrs [I ...

As heart failure patients, the TAVI population studied already is recommended to be treated with an SGLT2 inhibitor, noted ...

MSD will pay Hengrui Pharma $200m upfront, up to $1.77bn in development, regulatory and commercial milestones, and royalties ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Researchers examined the risk for serious infection among patients with atopic dermatitis treated with Janus kinase inhibitors vs Th2 cytokine inhibitors.

In just over a year since its US Food and Drug Administration (FDA) approval, pirtobrutinib (Jayprica) has become a standard ...

Among women with suspected ischemia with nonobstructive coronary disease, an intensive medical therapy strategy did not ...